Biocryst Pharmaceuticals (BCRX) Research & Development (2010 - 2026)
Biocryst Pharmaceuticals' Research & Development was $51.97 million in Q2 2026, up 19.8% from $43.39 million a year earlier but down 13.8% from the prior quarter.
Powered by 
Analysis
Biocryst Pharmaceuticals (BCRX) Research & Development (2010 - 2026) Analysis & Trends
On a trailing twelve-month basis, Biocryst Pharmaceuticals' Research & Development was $197.76 million through Jun 30, 2026, up 15.5% year-over-year; for FY2025, it came in at $166.13 million, down 4.9% from FY2024.
- Research & Development has now declined for three consecutive years, though with a five-year compound annual growth rate of 6.2% (FY2020 to FY2025).
- In earlier years, Research & Development was $174.64 million in FY2024 (-19.4%), $216.57 million in FY2023 (-14.5%), $253.3 million in FY2022 (+21.3%) and $208.81 million in FY2021 (+69.8%).
- Quarterly Research & Development has moved between $37.27 million (Q1 2025) and $73.21 million (Q4 2022) over five years.
- Compared with a year earlier, Research & Development was higher in four of the last eight quarters, with growth averaging 3.3%.
- The best year-over-year quarter for Research & Development over five years was Q4 2021 (growth of 79.7%); the worst was Q4 2024 (a decline of 29.4%).
- Per Business Quant data, BCRX's Research & Development in the three quarters before Q2 2026 was $60.32 million (Q1 2026), $40.87 million (Q4 2025) and $44.6 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 655.56 Bn | 574.09 Bn | 17.26 Bn | 3.65 Bn |
| 2 | AbbVie | 470.94 Bn | 444.10 Bn | 12.70 Bn | 2.34 Bn |
| 3 | Merck | 367.14 Bn | 321.57 Bn | 12.21 Bn | 9.74 Bn |
| 4 | Novartis Ag | 280.33 Bn | 236.20 Bn | 11.24 Bn | -2.85 Bn |
| 5 | Astrazeneca | 257.78 Bn | 231.34 Bn | 12.86 Bn | -4.05 Bn |
| 6 | Amgen | 226.04 Bn | 181.44 Bn | 7.24 Bn | 1.87 Bn |
| 7 | Gilead Sciences | 188.89 Bn | 163.01 Bn | 6.22 Bn | 1.76 Bn |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | 2.81 Bn |
| 9 | Vertex Pharmaceuticals | 133.68 Bn | 105.69 Bn | 2.84 Bn | 993.80 Mn |
| 10 | Biocryst Pharmaceuticals | 2.16 Bn | 1.08 Bn | 214.41 Mn | 51.97 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 51.97 Mn |
| Mar 31, 2026 | 60.32 Mn |
| Dec 31, 2025 | 40.87 Mn |
| Sep 30, 2025 | 44.60 Mn |
| Jun 30, 2025 | 43.39 Mn |
| Mar 31, 2025 | 37.27 Mn |
| Dec 31, 2024 | 49.44 Mn |
| Sep 30, 2024 | 41.08 Mn |
| Jun 30, 2024 | 37.62 Mn |
| Mar 31, 2024 | 46.49 Mn |
| Dec 31, 2023 | 70.05 Mn |
| Sep 30, 2023 | 46.88 Mn |
| Jun 30, 2023 | 51.25 Mn |
| Mar 31, 2023 | 48.39 Mn |
| Dec 31, 2022 | 73.21 Mn |
| Sep 30, 2022 | 52.74 Mn |
| Jun 30, 2022 | 61.99 Mn |
| Mar 31, 2022 | 65.36 Mn |
| Dec 31, 2021 | 63.53 Mn |
| Sep 30, 2021 | 49.97 Mn |
API Access
Biocryst Pharmaceuticals Research & Development API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=research-and-development&ticker=BCRX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "research-and-development", "ticker": "BCRX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=research-and-development&ticker=BCRX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();